Source Count: 14 | Weighted Score: 36 | Source Confidence: [4/5] | Primary Tier: 1 | Last Updated: April 19, 2026
Keywords: psychedelic medicine, psilocybin, johns hopkins, MDMA, therapeutic, clinical trials, depression, PTSD, roland griffiths, mystical experience
Category Tags: x5 specialized modern
Cross-References: Y_1_21 — Plant Alkaloids and Consciousness · K_3_15 — Psychedelic Neuroscience · X_3_08 — Cancer Research History

QUICK SUMMARY

The psychedelic therapy renaissance — centered at the Johns Hopkins Center for Psychedelic and Consciousness Research (established 2019, originally launched as a research program in 2000) — represents one of the most significant paradigm shifts in modern psychiatry. Roland Griffiths (1946–2023), who led the Hopkins program until his death, published landmark studies demonstrating that psilocybin, combined with psychological support, produces sustained improvements in treatment-resistant depression, end-of-life distress, smoking cessation, and existential anxiety. The FDA granted "Breakthrough Therapy" designation to psilocybin for treatment-resistant depression (2018) and MDMA for PTSD (2017). Phase 3 trials by MAPS (Multidisciplinary Association for Psychedelic Studies) for MDMA-assisted therapy showed 67% of PTSD participants no longer met diagnostic criteria at 18-month follow-up. This renaissance reverses decades of research prohibition following the Controlled Substances Act (1970).

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Established)

• KEY FINDING Roland Griffiths' 2006 study in Psychopharmacology — the first rigorous double-blind psilocybin study in nearly 40 years — demonstrated that psilocybin (30 mg/70 kg) produced mystical-type experiences in 72% of participants, with 67% rating it among the five most meaningful experiences of their lives at 14-month follow-up (Griffiths et al., 2006).
• KEY FINDING A 2020 randomized controlled trial at Johns Hopkins (n=24) found that psilocybin therapy produced rapid and sustained reductions in major depressive disorder (MDD) symptoms, with 71% of participants showing >50% reduction in GRID-HAMD scores at 4 weeks, maintained at 12 months. Effect sizes (Cohen's d = 2.3) substantially exceeded those of conventional antidepressants (Davis et al., 2021).
• Phase 3 clinical trials of MDMA-assisted therapy for PTSD conducted by MAPS demonstrated that 67% of participants (n=90) no longer met PTSD diagnostic criteria after three MDMA sessions plus preparatory/integration psychotherapy, compared to 32% in the placebo-with-therapy group (Mitchell et al., 2021).
• Psilocybin for smoking cessation at Johns Hopkins showed 80% abstinence at 6 months in an open-label pilot study (n=15), substantially exceeding standard pharmacotherapy success rates (~35% for varenicline). Matthew Johnson led this research (Johnson et al., 2014).
• The FDA granted Breakthrough Therapy designation to COMPASS Pathways' psilocybin for treatment-resistant depression in October 2018, and to MAPS' MDMA-assisted therapy for PTSD in August 2017, acknowledging that these substances may demonstrate substantial improvement over existing treatments.

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

• Neuroimaging studies using fMRI during psilocybin sessions show decreased activity and connectivity in the Default Mode Network (DMN), the brain system associated with self-referential thought and the narrative self. Robin Carhart-Harris (Imperial College London) proposed that DMN disruption mediates the ego-dissolution and therapeutic effects of psychedelics (Carhart-Harris et al., 2012).
• The "mystical experience" hypothesis — that therapeutic outcomes correlate with the intensity of the mystical-type experience during the session, not merely the pharmacological action — is supported by multiple studies. Griffiths et al. (2008) found that mystical experience scores predicted long-term positive changes in attitudes, mood, and behavior.
• Psilocybin may reduce alcohol use disorder (AUD): a 2022 JAMA Psychiatry RCT (n=93) found that psilocybin therapy reduced heavy drinking days by 83% at 8 months, compared to 51% for active placebo (diphenhydramine) with matched therapy (Bogenschutz et al., 2022).
• The "entropic brain" hypothesis (Carhart-Harris, 2014) proposes that psychedelics increase neural entropy (signal diversity), temporarily destabilizing rigid, maladaptive patterns of brain activity and enabling therapeutic reorganization. This is consistent with increased neural complexity measures under psilocybin but the mechanistic details remain debated.

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

• Whether psychedelic therapy could address neurodegenerative conditions (Alzheimer's, Parkinson's) through neuroplasticity enhancement is an emerging hypothesis. Preclinical evidence shows psilocybin promotes dendritic spine growth and BDNF release in mice, but human clinical evidence for neurodegenerative applications is absent (Ly et al., 2018).
• The long-term (10+ year) durability of single or few-session psychedelic interventions is unknown. Most follow-up data extends 12–18 months. Whether periodic "booster" sessions are needed is an open clinical question.
• Researchers propose that psychedelic experiences provide genuine metaphysical insight (the "perennial philosophy" interpretation), not merely therapeutic effect. This philosophical claim cannot be evaluated by clinical trial methodology and remains outside the scope of medical research.

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

• DEBUNKED The claim that psilocybin or LSD cause chromosome damage, brain lesions, or persistent psychosis in healthy populations was based on methodologically flawed studies from the 1960s–70s. Modern controlled published evidence demonstrates no evidence of lasting cognitive impairment or genetic damage at clinical doses (Johnson et al., 2018).
• Claims that psychedelics are universally safe ignore real risks: cardiac contraindications for MDMA (serotonergic cardiotoxicity), risk of prolonged psychosis in individuals with personal/family history of psychotic disorders, and rare but documented cases of Hallucinogen Persisting Perception Disorder (HPPD).

Counter-Arguments & Criticisms

• The FDA rejected MAPS' MDMA New Drug Application in August 2024, citing concerns about trial methodology (functional unblinding — most participants could tell they received MDMA), insufficient diversity in study populations, and potential for abuse. This regulatory setback highlights that psychedelic medicine faces higher evidentiary bars than initially anticipated.
• Expectancy and placebo effects are difficult to control in psychedelic trials because the subjective effects are unmistakable. Active placebos (niacin, low-dose psilocybin) only partially address this. Critics argue that reported effect sizes may be inflated by expectancy bias (Muthukumaraswamy et al., 2021).
• Scalability is uncertain: therapeutic psilocybin requires 6–8 hours of therapist support per session, intensive screening, and preparation/integration sessions. At $10,000–$25,000 per treatment course, access may be limited to affluent patients without insurance coverage or policy reform.
• Historical context matters: the first psychedelic therapy research wave (1950s–60s) collapsed not only due to prohibition but also due to poor methodology, inadequate safety protocols, and unethical practices. The current renaissance must avoid repeating these failures.

IMAGES

No images assigned yet.

BIBLIOGRAPHY

1. Bogenschutz, Michael, Ross, Stephen, Bhatt, Snehal, et al | 2022 | "Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients with Alcohol Use Disorder" | JAMA Psychiatry | ∅ | 79.10::953–962 | ∅ | ∅ | doi:10.1001/jamapsychiatry.2022.2096 | ∅ | ∅ | ∅
2. Carhart-Harris, Robin, Erritzoe, David, Williams, Tim, et al | 2012 | "Neural Correlates of the Psychedelic State as Determined by fMRI Studies with Psilocybin" | Proceedings of the National Academy of Sciences | ∅ | 109.6::2138–2143 | ∅ | ∅ | doi:10.1073/pnas.1119598109 | ∅ | ∅ | ∅
3. Carhart-Harris, Robin | 2014 | "The Entropic Brain: A Theory of Conscious States Informed by Neuroimaging Research with Psychedelic Drugs" | Frontiers in Human Neuroscience | ∅ | 8::20 | ∅ | ∅ | doi:10.3389/fnhum.2014.00020 | ∅ | ∅ | ∅
4. Davis, Alan, Barrett, Frederick, May, Darrick, et al | 2021 | "Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial" | JAMA Psychiatry | ∅ | 78.5::481–489 | ∅ | ∅ | doi:10.1001/jamapsychiatry.2020.3285 | ∅ | ∅ | ∅
5. Griffiths, Roland, Richards, William, McCann, Una; Jesse, Robert | 2006 | "Psilocybin Can Occasion Mystical-Type Experiences Having Substantial and Sustained Personal Meaning and Spiritual Significance" | Psychopharmacology | ∅ | 187.3::268–283 | ∅ | ∅ | doi:10.1007/s00213-006-0457-5 | ∅ | ∅ | ∅
6. Griffiths, Roland, Richards, William, Johnson, Matthew, McCann, Una; Jesse, Robert | 2008 | "Mystical-Type Experiences Occasioned by Psilocybin Mediate the Attribution of Personal Meaning and Spiritual Significance 14 Months Later" | Journal of Psychopharmacology | ∅ | 22.6::621–632 | ∅ | ∅ | doi:10.1177/0269881108094300 | ∅ | ∅ | ∅
7. Johnson, Matthew, Garcia-Romeu, Albert, Cosimano, Mary; Griffiths, Roland | 2014 | "Pilot Study of the 5-HT2AR Agonist Psilocybin in the Treatment of Tobacco Addiction" | Journal of Psychopharmacology | ∅ | 28.11::983–992 | ∅ | ∅ | doi:10.1177/0269881114548296 | ∅ | ∅ | ∅
8. Johnson, Matthew, Griffiths, Roland, Hendricks, Peter; Henningfield, Jack | 2018 | "The Abuse Potential of Medical Psilocybin According to the 8 Factors of the Controlled Substances Act" | Neuropharmacology | ∅ | 142::143–166 | ∅ | ∅ | doi:10.1016/j.neuropharm.2018.05.012 | ∅ | ∅ | ∅
9. Ly, Calvin, Greb, Alexandra, Cameron, Lindsay, et al | 2018 | "Psychedelics Promote Structural and Functional Neural Plasticity" | Cell Reports | ∅ | 23.11::3170–3182 | ∅ | ∅ | doi:10.1016/j.celrep.2018.05.022 | ∅ | ∅ | ∅
10. Mitchell, Jennifer, Bogenschutz, Michael, Lilienstein, Alia, et al | 2021 | "MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study" | Nature Medicine | ∅ | 27.6::1025–1033 | ∅ | ∅ | doi:10.1038/s41591-021-01336-3 | ∅ | ∅ | ∅
11. Muthukumaraswamy, Suresh, Forsyth, Anna; Lumley, Thomas | 2021 | "Blinding and Expectancy Confounds in Psychedelic Randomized Controlled Trials" | Expert Review of Clinical Pharmacology | ∅ | 14.9::1133–1152 | ∅ | ∅ | doi:10.1080/17512433.2021.1933434 | ∅ | ∅ | ∅
12. Pollan, Michael | 2018 | ∅ | How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence | ∅ | ∅ | New York: Penguin | ∅ | isbn:9780735224811 | ∅ | ∅ | ∅
13. Nutt, David, Erritzoe, David; Carhart-Harris, Robin | 2020 | "Psychedelic Psychiatry's Brave New World" | Cell | ∅ | 181.1::24–28 | ∅ | ∅ | doi:10.1016/j.cell.2020.03.020 | ∅ | ∅ | ∅
14. Griffiths, Roland, Johnson, Matthew, Carducci, Michael, et al | 2016 | "Psilocybin Produces Substantial and Sustained Decreases in Depression and Anxiety in Patients with Life-Threatening Cancer" | Journal of Psychopharmacology | ∅ | 30.12::1181–1197 | ∅ | ∅ | doi:10.1177/0269881116675513 | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Generated from V4 expansion plan. Last Updated: April 19, 2026